Literature Reviews
doi: 10.25005/2074-0581-2019-21-1-141-146
CLINICAL AND PHARMACOECONOMIC ASPECTS OF ACTIVE CONTROLLED ANTI-INFLAMMATORY THERAPY OF RHEUMATOID ARTHRITIS, BASED ON THE PRINCIPLES OF THE «TREAT-TO-TARGET» STRATEGY: CURRENT STATE OF THE ISSUE

S.B. Bekmurodzoda, Yo.U. Saidov, Kh.R. Makhmudov

Department of Propaedeutics of Internal Medicine, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

The review presents a detailed analysis and assessment of current views on the fundamental issues of the therapy of rheumatoid arthritis (RA) within the framework of the “treat-to-target” (T2T) strategy. The most significant principles of the strategy are the focus on preservation the patient’s quality of life, careful monitoring of the RA treatment process, and the active involvement of the patient in the treatment process. The results of the longterm study of the main issues related to the RA problem indicate that the cardinal improvement in the prognosis of the disease depends not only on the widespread use of innovative and often expensive drugs but more on the revision and improvement of traditional approaches and treatment strategies, and the disease in general. An analysis of the literature shows that the optimization of RA therapy within the framework of the T2T strategy dictates the need for full clinical and economic research aimed at finding the most effective and economically benign treatment regimens for the disease

Keywords: Rheumatoid arthritis, treat-to-target strategy, effectiveness evaluation, pharmacoeconomic aspects.

Download file:

References
  1. Nasonov EL. Problemy immunopatologii revmatoidnogo artrita: evolyutsiya bolezni [Problems of rheumatoid arthritis immunopathology: evolution of the disease]. Nauchno-prakticheskaya revmatologiya. 2017;55(3):277- 94. Available from: http://dx.doi.org/10.14412/1995-4484-2017-277- 294
  2. Carina AI, Svensson CI, Malmström V, Schett G, Klareskog L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Immunol. 2017;13(2):79-86. Available from: http:// dx.doi. org/10.1038/nrrheum.2016.200.
  3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. Available from: http://dx.doi.org/10.1016/ S0140-6736(16)30173-8.
  4. Balabanova RM, Erdes ShF. Dinamika rasprostranyonnosti revmaticheskikh zabolevaniy, vkhodyashchikh v ХIII klass MKB-10, v populyatsii vzroslogo naseleniya Rossiyskoy Federatsii na 2000-2010 g [Trends in the prevalence of rheumatic diseases in ICD-10 in the adult population of the Russian Federation over 2000-2010]. Nauchno-prakticheskaya revmatologiya. 2012;52(3):10-2.
  5. Avdeeva AS, Karateev DE, Denisov LN, Nasonov EL. Evropeyskiy kongress revmatologov (Parizh, 11-14 iyunya 2014 g.) – problemy revmatoidnogo artrita [The European Congress of Rheumatology (Paris, 11-14 June 2014): Problems of rheumatoid arthritis]. Nauchno-prakticheskaya revmatologiya. 2014;52(6):689-96.
  6. Panafidina TA, Kondratyeva LV, Gerasimova EV, Novikova DS, Popkova TV. Komorbidnost’ pri revmatoidnom artrite [Comorbidity in rheumatoid arthritis]. Nauchno-prakticheskaya revmatologiya. 2014;52(3):283-9. Available from: http://dx.doi.org/10.14412/1995-4484-2014-283-289.
  7. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmunnye revmaticheskie zabolevaniya: itogi i perspektivy nauchnykh issledovaniy [Autoimmune rheumatic diseases: Results and prospects for researches]. Nauchnoprakticheskaya revmatologiya. 2015;3:230-7.
  8. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for thе management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. Available from: http:// dx.doi.org/10.1136/annrheumdis-2016-210715.
  9. Karateev DE. Ostrye voprosy strategii lecheniya revmatoidnogo artrita [Treatment strategy for rheumatoid arthritis: hot topics]. Nauchnoprakticheskaya revmatologiya. 2015;9(1):84-92. Available from: http:// dx.doi.org/10.14412/1996-7012-2015-1-84-92
  10. Mazurov VI, Belyaeva IB, Oktyabrskaya IV. Sovremennaya strategiya lecheniya rannego revmatoidnogo artrita [Current treatment strategy for early rheumatoid arthritis]. Doktor Ru. 2014;7:28-32.
  11. Karateev DE, Luchikhina EL. Sovremennye printsipy vedeniya bol’nykh s revmatoidnym artritom [Modern principles of management of patients with rheumatoid arthritis]. Meditsinskiy sovet. 2017;17:92-101. Available from: http://dx.doi.org/10.21518/2079-701X-2017-17-92-100
  12. Nasonov EL, Karateev DE. Primenenie genno-inzhenernykh biologicheskikh preparatov dlya lecheniya revmatoidnogo artrita: obshchaya kharakteristika (lektsiya) [Use of genetically engineered biological agents for the treatment of rheumatoid arthritis: general characteristics (a lecture)]. Nauchnoprakticheskaya revmatologiya. 2013;51(2):163-9. Available from: http:// dx.doi.org/10.14412/1995-4484-2013-645
  13. Nasonov EL. Metotreksat pri revmatoidnom artrite – 2015: novye fakty i idei [Methotrexate in rheumatoid arthritis – 2015: New facts and ideas]. Nauchno-prakticheskaya revmatologiya. 2015;53(4):421-33. Available from: http://dx.doi.org/10.14412/1995-4484-2015-421-433.
  14. Nasonov EL, Karateev DE, Chichasova NV. Novye rekomendatsii po lecheniyu revmatoidnogo artrita (EULAR, 2013): mesto metotreksata [New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate]. Nauchno-prakticheskaya revmatologiya. 2014;52(1):8-26. Available from: http://dx.doi.org/10.14412/1995-4484- 2014-8-26.
  15. Karateev DE. Sovremennoe vedenie bol’nykh s rannim revmatoidnym artritom [Modern management of patients with early rheumatoid arthritis]. Rossiyskiy meditsinskiy zhurnal. 2014;7:483-7.
  16. Makhmudov KhR, Saidov YoU. Strategiya «Lechenie do dostizheniya tseli» v terapii revmatoidnogo artrita [Strategy «Treat to target» in the therapy of rheumatoid arthritis]. Vestnik Avitsenni [Avicenna Bulletin]. 2015;4:126-32
  17. Karateev DE, Luchikhina EL, Demidova NV, Gridneva GI, Kanonirova MA, Muravyov YuV, i dr. Pervoe Rossiyskoe strategicheskoe issledovanie farmakoterapii revmatoidnogo artrita (REMARKA): rezul’taty lecheniya 130 bol’nykh v techenie 12 mesyatsev [The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA trial): Results of 12-month treatment in 130 patients]. Nauchno-prakticheskaya revmatologiya. 2014;52(6):607-14
  18. Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, et al. Characterizing deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Res Ther. 2015;17:48-60. Available from: http://dx.doi.org/10.1186/s13075-015-0562-0.
  19. Solomon DH, Bitton A, Katz JN, Radner H, Brown E, Fraenkel L. Treat to Target in rheumatoid arthritis: facts, fiction or hypothesis. Arthritis Rheumatol. 2014;66(4):775-82. Available from: http://dx.doi.org/10.1002/art.38323.
  20. Olyunin YuA. Otsenka aktivnosti zabolevaniya pri revmatoidnom artrite: rekomendatsii i praktika [Assessment of disease activity in rheumatoid arthritis: recommendations and practice]. Sovremennaya revmatologiya. 2014;8(2):4-9.
  21. Zinchuk IYu, Amirdzhanova VN. Sotsial’noe bremya revmatoidnogo artrita [Social burden of rheumatoid arthritis]. Nauchno-prakticheskaya revmatologiya. 2014;52(3):331-5. Available from: http://dx.doi. org/10.14412/1995-4484-2014-331-335.
  22. Gábor F, Somogyi А, Szekanecz Z. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. Clinical Rheumatology. 2014;33(5):623-9.
  23. Goryachev DV, Erdes ShF, Nasonov EL. Farmakoekonomicheskiy analiz primeneniya Totsilizumaba v terapii revmatoidnogo artrita, imitatsionnoe modelirovanie [Pharmacoeconomic analysis of the use of tocilizumab in therapy for rheumatoid arthritis: imitation simulation]. Nauchnoprakticheskaya revmatologiya. 2010;2:87-102.
  24. Gridneva GI, Muravyov YuV, Luchikhina EL, Demidova NV, Karateev DE. Voprosy optimizatsii terapii metotreksatom u bol’nykh revmatoidnym artritom [Issues of optimization of methotrexate therapy in patients with rheumatoid arthritis]. Nauchno-prakticheskaya revmatologiya. 2017;55(1):41-7. Available from: http://dx.doi.org/10.14412/1995-4484- 2017-41-47.
  25. Lila AM, Dreval RO, Shipitsyn VV. Otsenka organizatsii meditsinskoy pomoshchi i lekarstvennogo obespecheniya pri revmaticheskikh zabolevaniyakh i sotsial’no-ekonomicheskogo bremeni etikh bolezney v Rossiyskoy Federatsii [Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation]. Sovremennaya revmatologiya. 2018;12(3):112- 9. Available from: http://dx.doi.org/10.14412/1996-7012-2018-3-112-119.
  26. Volkova MV, Kunder EV. Effektivnost’ lecheniya revmatoidnogo artrita bazisnymi lekarstvennymi sredstvami: rezul’taty prospektivnogo nablyudeniya v usloviyakh real’noy klinicheskoy praktiki [Efficiency of treatment of rheumatoid arthritis by synthetic basic anti-inflammatory drugs: the results of prospective observation in real clinical practice]. Retsept. 2018;21(6):827-33.
  27. Zinchuk IYu. Rezul’taty otsenki pryamykh zatrat na lechenie revmatoidnogo artrita s ispol’zovaniem genno-inzhenernykh biologicheskikh preparatov [The assessment of direct costs for treatment of rheumatoid arthritis using a genetically engineered biological agents]. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2012;5(1):51-2.
  28. Zinchuk IYu, Khabriev RU. Aktual’nost’ farmakoekonomicheskoy otsenki terapii yuvenil’nogo revmatoidnogo artrita [The relevance of pharmacoeconomic evaluation of treatment of juvenile rheumatoid arthritis]. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2010;3(1):58-9.
  29. Yagudina RI, Zinchuk IYu, Litvinenko МM. Analiz «stoimosti bolezni»: vidy, metodologiya, osobennosti provedeniya v Rossiyskoy Federatsii [Cost of illness analysis: types, methodology, specifics in Russian Federation]. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2012;5(1):4-9

Authors' information:

Bekmurodzoda Sulton Begmurod
Competitor of the Department of Propedeutics of Internal Diseases, Avicenna Tajik State Medical University

Saidov Yor Umarovich
Doctor of Medical Sciences, Head of the Department of Propedeutics of Internal Diseases, Avicenna Tajik State Medical University

Makhmudov Khayom Ruziboevich
Candidate of Medical Sciences, Assistant of the Department of Propedeutics of Internal Diseases, Avicenna Tajik State Medical University

Conflicts of interest: No conflict

Address for correspondence:

Saidov Yor Umarovich
Doctor of Medical Sciences, Head of the Department of Propedeutics of Internal Diseases, Avicenna Tajik State Medical University

734003, Republic of Tajikistan, Dushanbe, Rudaki Ave., 139

Tel.: 992 (918) 694819

E-mail: erumarovich@mail.ru

◄ Back to the list